AVTX
Avalo Therapeutics, Inc. NASDAQ Listed Oct 14, 2015$22.87
After hrs
$21.20
-1.71%
Mkt Cap $258.3M
52w Low $3.39
93.3% of range
52w High $24.27
50d MA $15.34
200d MA $14.41
P/E (TTM)
-2.4x
EV/EBITDA
-3.2x
P/B
2.2x
Debt/Equity
0.0x
ROE
-94.2%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.94
50d MA
$15.34
200d MA
$14.41
Avg Volume
686.1K
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
540 Gaither Road · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -1.54 | -0.37 | +76.0% | 13.50 | +0.0% | -0.4% | +3.3% | +3.3% | +2.9% | +3.2% | — |
| Nov 6, 2025 | AMC | -1.67 | -2.19 | -31.1% | 15.42 | -0.6% | -2.4% | -1.3% | +0.5% | +0.1% | -4.5% | — |
| Aug 7, 2025 | AMC | -1.43 | -1.92 | -34.3% | 8.35 | +4.9% | +6.9% | +7.9% | +12.1% | +8.6% | +7.2% | — |
| May 12, 2025 | AMC | -1.07 | -1.25 | -16.8% | 4.00 | +0.0% | -8.0% | -10.0% | -3.5% | -2.2% | +0.0% | — |
| Apr 4, 2025 | AMC | 0.58 | -7.95 | -1470.7% | 5.80 | -1.6% | -0.7% | -5.3% | -12.1% | -14.8% | -15.5% | — |
| Nov 7, 2024 | AMC | -1.19 | -2.83 | -137.8% | 12.91 | -7.0% | +3.1% | +2.6% | -0.8% | +3.8% | +4.4% | — |
| Aug 12, 2024 | AMC | -6.70 | -14.07 | -110.0% | 9.90 | +5.8% | -0.2% | +2.7% | -6.1% | -8.4% | -6.6% | — |
| Jul 11, 2024 | AMC | — | -141.14 | — | 12.00 | +4.2% | +1.3% | +5.4% | +4.2% | +8.2% | +4.2% | — |
| May 13, 2024 | AMC | -1.18 | -5.98 | -406.8% | 10.82 | -3.4% | -2.0% | -4.0% | -10.9% | -11.4% | +2.6% | — |
| Nov 9, 2023 | AMC | -261.90 | -26.19 | +90.0% | 23.52 | -1.0% | -8.2% | -7.1% | +1.0% | +1.0% | -6.1% | — |
| Aug 3, 2023 | AMC | -214.29 | -140.48 | +34.4% | 47.52 | +0.5% | -11.6% | -19.2% | -16.2% | -22.7% | -26.8% | — |
| May 4, 2023 | AMC | -230.95 | -202.38 | +12.4% | 676.80 | -2.8% | -7.8% | -6.4% | -8.2% | -12.6% | -14.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $13.66 | $13.54 | -0.9% | -2.3% | +1.8% | -2.3% | +5.6% | +5.6% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $14.26 | +6.0% | +3.7% | +3.7% | +3.3% | +3.6% | +11.0% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $13.50 | $13.50 | +0.0% | -0.4% | +3.3% | +3.3% | +2.9% | +3.2% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.19 | $16.21 | +0.1% | -3.4% | -7.0% | -8.6% | -2.7% | +0.4% |
| Sep 29 | BTIG | Maintains | Buy → Buy | — | $10.80 | $13.30 | +23.1% | +20.6% | +17.7% | +20.0% | +20.4% | +24.1% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.76 | $9.84 | +0.8% | +16.1% | +21.7% | +21.2% | +19.9% | +15.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.99 | $7.65 | -4.3% | +2.9% | -4.1% | -4.5% | +6.9% | +4.6% |
| Apr 16 | Oppenheimer | Upgrade | Perform → Outperform | — | $15.24 | $16.90 | +10.9% | +4.6% | -10.6% | -21.2% | -23.7% | -19.9% |
| Jun 26 | Oppenheimer | Downgrade | Outperform → Perform | — | $1060.80 | $182.88 | -82.8% | -88.7% | -90.3% | -90.4% | -91.6% | -92.0% |
| Jun 26 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $1060.80 | $182.88 | -82.8% | -88.7% | -90.3% | -90.4% | -91.6% | -92.0% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $633.60 | $624.00 | -1.5% | -1.9% | -6.6% | -9.1% | -6.8% | +4.2% |
| Feb 7 | Jefferies | Downgrade | Hold → Underperform | — | $837.60 | $847.20 | +1.1% | -0.9% | -8.3% | -8.3% | -10.0% | -14.6% |
| Mar 3 | Jefferies | Downgrade | Buy → Hold | — | $2249.28 | $2217.60 | -1.4% | -8.3% | -9.1% | -14.2% | -10.4% | -7.6% |
| Mar 3 | RBC Capital | Maintains | Outperform → Outperform | — | $2249.28 | $2217.60 | -1.4% | -8.3% | -9.1% | -14.2% | -10.4% | -7.6% |
| Sep 24 | RBC Capital | Maintains | Outperform → Outperform | — | $7084.80 | $7027.20 | -0.8% | -2.0% | -1.2% | -5.3% | -8.5% | -11.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 8,900 | $22.57 | $201K | 423 | -5.68% | — |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 9,219 | $21.37 | $197K | 9,323 | -5.68% | — |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 2,700 | $20.76 | $56K | 18,542 | -5.68% | — |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 12,347 | $19.28 | $238K | 21,242 | -5.68% | — |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 13,834 | $18.55 | $257K | 33,589 | -5.68% | — |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 10,058 | $22.88 | $230K | 3,622 | -5.68% | — |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 19,015 | $22.41 | $426K | 13,680 | -5.68% | — |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 44,944 | $21.20 | $953K | 32,695 | -5.68% | — |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 5,000 | $19.65 | $98K | 77,639 | -5.68% | — |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 27,538 | $18.03 | $496K | 82,639 | -5.68% | — |
| May 6, 2026 | Chan Mitchell | — | Sell | 3,167 | $22.88 | $72K | 3,166 | -5.68% | — |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | Sell | 400 | $23.71 | $9K | 3,634 | -5.68% | — |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | Sell | 9,253 | $22.70 | $210K | 4,034 | -5.68% | — |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | Sell | 22,839 | $21.22 | $485K | 13,287 | -5.68% | — |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | Sell | 5,196 | $19.78 | $103K | 36,126 | -5.68% | — |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | Sell | 37,375 | $18.91 | $707K | 41,322 | -5.68% | — |
| May 5, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,679 | $16.00 | $27K | 3,622 | -5.68% | — |
| Apr 30, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 8,457 | $13.23 | $112K | 423 | +0.51% | +57.33% |
| Apr 29, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 8,458 | $13.09 | $111K | 8,880 | +0.51% | +57.33% |
8-K · 2.02
!! High
Avalo Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Avalo Therapeutics disclosed Q1 2026 financial results in a prospectus supplement filed for a securities offering, revealing updated operational and financial performance metrics to potential investors.
May 7
8-K · 8.01
!! High
Avalo Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Avalo Therapeutics posted positive Phase 2 LOTUS trial topline results, potentially validating its therapeutic approach and supporting future clinical advancement and investor confidence.
May 5
8-K · 1.01
!! High
Avalo Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Avalo Therapeutics agreed to a $15 million milestone buyout option, expanding its financial obligations and potentially diluting shareholder value depending on whether the option gets exercised.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
AVTX's executive departure (item 5.02) signals potential leadership instability or strategic shifts that could impact operational execution and investor confidence in near-term performance.
Mar 27
8-K
Unknown — 8-K Filing
Avalo's $98 million cash position provides sufficient runway through 2028, reducing near-term financing risk and allowing investors to focus on clinical trial progress for its IL-1 inflammatory disease pipeline.
Mar 23
Data updated apr 24, 2026 8:04pm
· Source: massive.com